,
, Cancer incidence and mortality in France over the period 1980-2005. Rev Epidemiol Sante Publique, vol.56, pp.159-75, 2008.
,
, Estimates of Young Breast Cancer Survivors at Risk for Infertility in the U.S. The Oncologist, vol.19, pp.814-836, 2014.
Cancer incidence and mortality in France over the 1980-2012 period: solid tumors, Rev Epidemiol Sante Publique, vol.62, issue.2, pp.95-108, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01915012
,
, Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation, J Clin Oncol Off J Am Soc Clin Oncol, vol.31, issue.31, pp.3914-3923, 2013.
,
Impact of chemotherapy-induced amenorrhea in breast cancer patients: the evaluation of ovarian function by menstrual history and hormonal levels, World J Surg Oncol, vol.11, p.101, 2013. ,
Prognostic Effects of Adjuvant ChemotherapyInduced Amenorrhea and Subsequent Resumption of Menstruation for Premenopausal Breast Cancer Patients. Medicine (Baltimore), vol.95, p.3301, 2016. ,
,
, Pregnancy after breast cancer in germany-results of a retrospective database analysis
, Z Geburtshilfe Neonatol, vol.219, issue.4, pp.176-80, 2015.
Pregnancy after treatment of breast cancer in young women does not adversely affect the prognosis ,
, Breast Edinb Scotl, vol.21, issue.3, pp.272-277, 2012.
Motherhood after breast cancer: searching for la dolce vita, Expert Rev Anticancer Ther, vol.11, issue.2, pp.287-98, 2011. ,
, Ministère des affaires sociales et de la santé, 2014.
,
, Recommendations for fertility preservation in patients with lymphoma, leukemia, and breast cancer, J Assist Reprod Genet, vol.29, issue.6, pp.465-473, 2012.
Potential options for preservation of fertility in women, N Engl J Med ,
, Jul, vol.7, issue.1, pp.64-73
,
, Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy, Breast Cancer Res Treat, 2017.
,
, Erratum to: Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy, Breast Cancer Res Treat, vol.165, issue.1, p.161, 2017.
The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review, Hum Reprod Oxf Engl, vol.32, issue.5, pp.1033-1078, 2017. ,
Ovarian stimulation for fertility preservation in patients with cancer, Fertil Steril, vol.93, issue.3, pp.865-873, 2010. ,
Ovarian stimulation for fertility preservation in patients with cancer, Fertil Steril, vol.93, issue.3, pp.865-873, 2010. ,
,
Stimulation of the ovaries in women with breast cancer undergoing fertility preservation: Alternative versus standard stimulation protocols; the study protocol of the STIM-trial, Contemp Clin Trials, vol.61, pp.96-100, 2017. ,
GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation, Reprod Biomed Online, vol.20, issue.6, pp.783-791, 2010. ,
,
, Obstetric outcome after oocyte vitrification and warming for fertility preservation in women with cancer, Reprod Biomed Online, vol.29, issue.6, pp.722-730, 2014.
Oncofertility: an emerging discipline in obstetrics and gynecology, Obstet Gynecol Surv, vol.68, issue.8, pp.582-93, 2013. ,
,
, Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment, Fertil Steril, vol.97, issue.4, pp.930-934, 2012.
Fertility preservation for female cancer patients: early clinical experience, Fertil Steril, vol.94, issue.1, pp.149-55, 2010. ,
Response to ovarian stimulation is not impacted by a breast cancer diagnosis. Hum Reprod Oxf Engl, vol.32, pp.568-74, 2017. ,
Effects of cancer on ovarian response in controlled ovarian stimulation for fertility preservation ,
, Fertil Steril, vol.98, issue.4, pp.957-60, 2012.
Oocyte cryopreservation: where are we now? Hum Reprod Update, vol.22, pp.440-449, 2016. ,
Efficiency of oocyte cryopreservation: a metaanalysis, Fertil Steril, vol.86, issue.1, pp.70-80, 2006. ,
,
, Embryo development of fresh "versus" vitrified metaphase II oocytes after ICSI: a prospective randomized sibling-oocyte study, Hum Reprod Oxf Engl, 2010.
Clinical application of oocyte vitrification: a systematic review and meta-analysis of randomized controlled trials, Fertil Steril, vol.96, issue.2, pp.277-85, 2011. ,
Pregnancy after human oocyte cryopreservation, Lancet Lond Engl ,
, Apr, vol.19, issue.8486, pp.884-890
Over 900 oocyte cryopreservation babies born with no apparent increase in congenital anomalies, Reprod Biomed Online, 2009. ,
Obstetric and perinatal outcome of babies born from vitrified oocytes, Fertil Steril, 2014. ,
Oocyte cryopreservation for donor egg banking, Reprod Biomed Online, vol.23, issue.3, pp.341-347, 2011. ,
, Practice Committee of ASRM. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion, Fertil Steril, 2013.
, ACOG: Committee Opinion No. 584: oocyte cryopreservation, Obstet Gynecol
Live birth after the transfer of human embryos developed from cryopreserved oocytes harvested before cancer treatment, Fertil Steril, vol.87, issue.6, pp.1469-1470, 2007. ,
,
, Healthy twins delivered after oocyte cryopreservation and bilateral ovariectomy for ovarian cancer, Reprod Biomed Online, vol.17, issue.2, pp.265-272, 2008.
Twins born after transplantation of ovarian cortical tissue and oocyte vitrification, Fertil Steril, vol.93, issue.1, pp.268-279, 2010. ,
Live birth with marrow transplantation, J Assist Reprod Genet, vol.28, issue.12, pp.1167-70, 2011. ,
,
, Five years' experience using oocyte vitrification to preserve fertility for medical and nonmedical indications, Fertil Steril, vol.99, issue.7, pp.1994-2003, 2013.
Live birth using vitrified-warmed oocytes in invasive ovarian cancer: case report and literature review, Reprod Biomed Online, vol.28, issue.6, pp.663-671, 2014. ,
Live birth after 6 years of oocyte vitrification in a survivor with breast cancer, J Assist Reprod Genet, vol.31, issue.10, pp.1397-400, 2014. ,
Anti-Müllerian hormone (AMH) is a strong predictor of live birth in women undergoing assisted reproductive technology, Reprod Biol, vol.14, issue.3, pp.176-81, 2014. ,
AMH as a Prognostic Factor for Blastocyst Development, JBRA Assist Reprod, vol.19, issue.3, pp.131-135, 2015. ,
Anti-Mullerian Assist Reprod Genet, vol.28, pp.651-657, 2011. ,
,
AMH): a reliable biomarker of oocyte quality in IVF, J Assist Reprod Genet, vol.31, issue.4, pp.493-501, 2014. ,
,
, AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. Hum Reprod Update, vol.17, pp.46-54, 2011.
Serum AMH level as a marker of acute and long-term effects of chemotherapy on the ovarian follicular content: a systematic review, Reprod Biol Endocrinol RBE, vol.12, p.26, 2014. ,
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, vol.235, issue.4785, pp.177-82, 1987. ,
The ErbB signaling network: receptor heterodimerization in development and cancer, EMBO J, vol.3, issue.13, pp.3159-67, 2000. ,
,
, HER2 gene expression status in breast cancer by fluorescence in-situ hybridization
, Zhonghua Bing Li Xue Za Zhi, vol.34, issue.11, pp.701-706, 2005.
Moderate level of HER2 expression and its prognostic significance in breast cancer with intermediate grade, Breast Cancer Res Treat, vol.151, issue.2, pp.357-64, 2015. ,
Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers, J Clin Oncol Off J Am Soc Clin Oncol, vol.26, issue.35, pp.5697-704, 2008. ,
,
, Evolution of anti-HER2 therapies for cancer treatment, Cancer Treat Rev, 2017.
Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years, Br J Cancer, vol.11, issue.3, pp.359-77, 1957. ,
Pathological prognostic factors in breast cancer ,
, Crit Rev Oncol Hematol, vol.31, issue.3, pp.209-232, 1999.
,
, Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern Cooperative Oncology Group Companion Study, EST 4189, J Clin Oncol Off J Am Soc Clin Oncol, vol.18, issue.10, pp.2059-69, 2000.
,
, Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies, J Clin Invest, vol.121, issue.7, pp.2750-67, 2011.
,
, Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph nodenegative breast cancer, J Natl Cancer Inst, vol.91, issue.3, pp.271-279, 1999.
,
, Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients, Br J Cancer, vol.96, issue.10, pp.1504-1517, 2007.
,
, Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review, Breast Cancer Res Treat, vol.132, issue.3, pp.895-915, 2012.
Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients, Breast Edinb Scotl, vol.17, issue.4, pp.323-357, 2008. ,
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, Ann Oncol Off J Eur Soc Med Oncol, vol.24, issue.9, pp.2206-2229, 2013. ,
,
, Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St
, Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer
, Ann Oncol Off J Eur Soc Med Oncol, vol.22, issue.8, pp.1736-1783, 2011.
A cytohistological study of Ki-67 expression in ovarian tumors, Indian J Pathol Microbiol, vol.54, issue.1, pp.21-25, 2011. ,
, CSHG de l'ovaire : une faible expression de Ki67 liée à la résistance au platine et à une survie moindre
, CSHG de l'ovaire : une faible expression de Ki67
, liée à la résistance au platine et à une survie moindre | Univadis, 2017.
Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE, J Natl Cancer Inst, vol.105, issue.5, pp.812-834, 2013. ,
,
, Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies, Am J Hum Genet, vol.72, issue.5, pp.1117-1147, 2003.
,
Premature Menopause in Patients with BRCA1 Gene Mutation, Breast Cancer Res Treat, vol.100, issue.1, pp.59-63, 2006. ,
,
,
,
Telomeres and human reproduction, Fertil Steril, vol.99, issue.1, pp.23-32, 2013. ,
, Association, vol.1, issue.2
, mutations with FMR1 genotypes: effects on menarcheal and menopausal age, Maturitas, p.45
Age-related decline in DNA repair function explains diminished ovarian reserve, earlier menopause, and possible oocyte vulnerability to chemotherapy in women with BRCA mutations, J Clin Oncol Off J Am Soc Clin Oncol, vol.32, issue.10, pp.1093-1097, 2014. ,
,
, BRCA mutation carriers show normal ovarian response in in vitro fertilization cycles
, Fertil Steril, vol.104, issue.5, pp.1162-1169, 2015.
Live birth rates in the different combinations of the Bologna criteria poor ovarian responders: a validation study, J Assist Reprod Genet, vol.32, issue.6, pp.931-938, 2015. ,
Accumulation of oocytes: a new strategy for managing low-responder patients, Reprod Biomed Online, 2012. ,
,
, ESHRE consensus on the definition of "poor response" to ovarian stimulation for in vitro fertilization: the Bologna criteria, Hum Reprod, vol.26, issue.7, pp.1616-1640, 2011.